Uti fusion proteins
US-2018072795-A1 · Mar 15, 2018 · US
Heparin/heparan sulfate-dependent inhibitors of activated protein C and uses thereof in treating hemophilic disorders
US9206246B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9206246-B2 |
| Application number | US-201314081427-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 15, 2013 |
| Priority date | Nov 16, 2012 |
| Publication date | Dec 8, 2015 |
| Grant date | Dec 8, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods for inhibiting activated protein C (APC) comprising contacting the APC with a Kunitz polypeptide in an amount effective in inhibiting the activity of APC, wherein the Kunitz polypeptide comprises six cysteine residues at positions corresponding to positions 7, 16, 32, 40, 53, and 57 in SEQ ID NO:1, a motif X 1 GX 2 CBX′ at positions corresponding to positions 13-18 in SEQ ID NO:1, wherein each of X 1 and X 2 , independently, is any amino acid residue, B is a basic amino acid residue, and X′ is G, A, or V; and at least one heparin-binding motif, which can present at the C-terminus of the Kunitz polypeptide.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for inhibiting activated protein C (APC), comprising contacting the APC with a Kunitz polypeptide in an amount effective in inhibiting the activity of APC, wherein: the Kunitz polypeptide comprises the amino acid sequence of SEQ ID NO:1. 2. The method of claim 1 , wherein the contacting step is performed by administering to a subject in need thereof the Kunitz polypeptide. 3. The method of claim 2…
Assignees
Inventors
Classifications
- C07K14/8114Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9206246B2 cover?
- Methods for inhibiting activated protein C (APC) comprising contacting the APC with a Kunitz polypeptide in an amount effective in inhibiting the activity of APC, wherein the Kunitz polypeptide comprises six cysteine residues at positions corresponding to positions 7, 16, 32, 40, 53, and 57 in SEQ ID NO:1, a motif X 1 GX 2 CBX′ at positions corresponding to positions 13-18 in SEQ ID NO:1, where…
- Who is the assignee on this patent?
- Academia Sinica
- What technology area does this patent fall under?
- Primary CPC classification C07K14/8114. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).